Diffusive Flux Analysis of Tumor Vascular Permeability for 3-Helix-Micelles in Comparison to Other Nanoparticles

Marc Lim, Vishnu Dharmaraj, Boying Gong, Ting XubioRxiv 2019 · DOI

TL;DR

This paper introduces a simplified mathematical model to analyze nanoparticle transport into tumors, focusing on diffusive flux. By applying this model to existing biodistribution data, the authors can extract a key parameter, effective vascular permeability (Peff), for various nanoparticles and tumor types, offering a more accessible tool for nanomedicine development.

What Problem Does This Paper Address?

Developing effective cancer nanomedicine hinges on understanding how nanoparticles navigate the complex tumor microenvironment. Solid tumors often have high interstitial pressure, hindering fluid movement and making diffusion the primary transport mechanism, especially in necrotic areas. This makes it challenging to deliver drugs to the tumor core. While the Enhanced Permeability and Retention (EPR) effect is known, precisely quantifying the factors that govern nanoparticle extravasation and accumulation, like particle permeability, has been difficult. Traditional methods, such as intravital microscopy, are specialized and labor-intensive. This paper aims to bridge this gap by providing a simpler, more accessible method to quantify nanoparticle permeability using readily available biodistribution data.

Methods

The core of this work is a diffusive flux model derived from the Staverman-Kedem-Katchalsky equation. The authors simplify this by assuming that in many tumor types, especially those with high interstitial pressure, convective transport is negligible, leaving diffusive flux as the dominant mechanism. This leads to a simplified equation where nanoparticle flux into the tumor is proportional to the permeability of the tumor vasculature and the concentration gradient between the blood and the tumor.

The authors then extract plasma pharmacokinetics (PK) data (concentration over time in the blood) and tumor accumulation data (concentration over time in the tumor) from published literature. They fit the PK data to a single exponential decay model to determine the particle's plasma elimination rate constant (K) and initial plasma concentration (Co). Subsequently, they fit the tumor accumulation data to their derived diffusive flux equation, using the determined K and Co, to solve for the effective vascular permeability (Peff). This approach allows them to decouple the influence of plasma half-life from particle permeability on tumor accumulation.

Datasets

The study utilizes data extracted from 37 published research papers found in the Cancer Nanomedicine Repository. These papers provided in vivo biodistribution data, including plasma pharmacokinetics and tumor accumulation over time for various nanoparticles in different tumor models. The authors specifically highlight their analysis of data for 3-helix-micelles (3HM) in U87MG glioblastoma and NDL breast tumor models, as well as data for Dextran particles and other nanoparticles from literature.

Key Insights and Ideas

  • Diffusion is King (in many tumors): The model's success in fitting data for certain tumor types (like GBM) suggests that diffusion is indeed the dominant transport mechanism, simplifying the complex reality of tumor microenvironment interactions.
  • Peff as a Universal Metric: The ability to extract a single "effective vascular permeability" (Peff) value allows for direct, quantitative comparison of how easily different nanoparticles can cross tumor vasculature, regardless of their specific composition or the experimental setup used in the original studies.
  • Decoupling PK from Permeability: This model provides a powerful way to separate the impact of how long a nanoparticle stays in circulation (plasma half-life) from how well it can get into the tumor (permeability). This is crucial for designing nanoparticles with optimal tumor targeting.
  • Size Matters (Sometimes): While particle size is often considered critical, the study found that for some tumor types (like colon cancer), permeability was relatively independent of size for particles up to 100 nm. However, for pancreatic and GBM tumors, a size-exclusion effect was observed, with larger particles showing lower permeability.
  • Tumor Heterogeneity is Real: The significant variability in Peff values observed across different tumor models, and even within the same tumor type with different particles, underscores the inherent heterogeneity of tumors and the need for tailored nanomedicine approaches.

Key Results

  • The diffusive flux model provided a good fit for 3HM nanoparticle transport in U87MG glioblastoma tumors, yielding an effective vascular permeability (Peff) of 2.31 ± 0.18 x 10⁻⁸ cm/s.
  • For HT29 colon cancer murine models, 3HM showed a Peff of 4.25 ± 0.91 x 10⁻⁸ cm/s.
  • The model successfully reproduced trends reported in the literature regarding the impact of particle size and tumor type on permeability. For example, breast tumors generally exhibited higher Peff than colon, pancreatic, and GBM tumors.
  • The study demonstrated that for particles around 100 nm, Peff was similar across different particle types (liposomes, dendrimers, micelles) in colon cancer models, but varied significantly in breast, pancreatic, and GBM models.
  • In comparing different labeling techniques for liposomes, the model showed that differences in tumor accumulation were primarily due to plasma clearance rather than changes in particle permeability.

Limitations and Future Work

  • Model Simplification: The model assumes diffusion is the dominant transport mechanism, which may not hold true for all tumor types or under all conditions (e.g., if convection is significant). The authors acknowledge that "poorer fits" in some models (like NDL breast cancer) might indicate the influence of other factors.
  • Data Quality and Variability: The analysis relies on data from various published studies, which may have inherent differences in experimental methods, measurement techniques, and tumor models, leading to variability in the extracted Peff values.
  • Tumor Vessel Contribution: The analysis might not fully exclude contributions from particles within tumor vessels, especially if PET signal correction for vasculature is not performed.
  • Future Work: The authors suggest that further analysis with controlled experiments is needed to confirm the findings. They also highlight the potential for this simple model to be applied to a larger body of nanoparticle data, enabling broader comparisons and aiding in the design of more effective nanomedicines. The development of more elaborate models that incorporate convective fluxes and compartmental analysis is also mentioned as a future direction.

Summary updated

Abstract

Abstract Understanding the complex interplay of factors affecting nanoparticle accumulation in solid tumors is a challenge that must be surmounted to develop effective cancer nanomedicine. The tumor microenvironment is unique in comparison to healthy tissue, possessing elevated interstitial pressure that limits convective transport, hence leaving diffusive processes to predominate especially in the tumor’s necrotic core. Certain tumor types such as glioblastoma multiforme and pancreatic tumor are known to be poorly permeable, making them less accessible for nanoparticle drug delivery. Evidence indicates that small and long-circulating nanoparticles are ideal for taking advantage of the enhanced permeability and retention effect, even in such intractable tumor models. Three-helix-micelle (3HM) self-assembled nanoparticles possess these characteristics, and previous studies have shown that 3HM can achieve more favorable tumor accumulation and penetration than liposomes in several tumor models. The reason for its superior performance had yet to be determined, and thus we sought to examine its passive transport into tumors. In this paper we present a simple mathematical model based on diffusive flux to describe particle accumulation in tumors with respect to particle plasma pharmacokinetics. Fitting the diffusive flux equation to in vivo particle tumor concentration yields the particle effective permeability value, which for 3HM is 2.31 ± 0.18 x 10 −8 cm/s in U87MG glioblastoma and 4.25 ± 0.91 x 10 −8 cm/s in HT29 colon cancer murine models. Applying this diffusive flux model to other nanoparticles reported in literature enables the effect of plasma half-life to be decoupled from particle permeability in influencing tumor accumulation, reinforced trends reported in the field regarding the impact of particle size, and provided a semi-quantitative means of comparing various tumor models. This work is also the first demonstration, to the best our knowledge, of extracting particle permeability values from bulk biodistribution data obtained via positron emission tomography, as opposed to laborious tumor optical window intravital microscopy experiments. As such the analysis provided here presents a simple and accessible tool to further enhance nanomedicine development. Abstract Figure Graphical abstract
BibTeX
@misc{lim2019diffusive,
  author = {Marc Lim and Vishnu Dharmaraj and Boying Gong and Ting Xu},
  title = {{Diffusive Flux Analysis of Tumor Vascular Permeability for 3-Helix-Micelles in Comparison to Other Nanoparticles}},
  year = {2019},
  doi = {10.1101/708263},
  howpublished = {bioRxiv},
}
Figure